Immatics NV (IMTX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Immatics NV (IMTX)
Company Performance

Current Price

as of Oct 16, 2024

$9.45

P/E Ratio

N/A

Market Cap

$1.13B

Description

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.

Metrics

Overview

  • HQTuebingen, BW
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerIMTX
  • Price$9.45-0.42%

Trading Information

  • Market Cap$1.13B
  • Float69.90%
  • Average Daily Volume (1m)746,242
  • Average Daily Volume (3m)475,986
  • EPS-$0.90

Company

  • Revenue$76.61M
  • Rev Growth (1yr)-17.01%
  • Net Income-$19.40M
  • Gross MarginN/A
  • EBITDA Margin-125.23%
  • EBITDA-$25.28M
  • EV$667.07M
  • EV/Revenue8.71
  • P/EN/A
  • P/S12.71
  • P/B2.34
Documents